Genetic Analysis AS
The answer first
Does Genetic Analysis beat the market?
No, Genetic Analysis has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 8% of Nordic stocks
- Quality40
- Value18
- Trend19
No. 167 of 195 in healthcare
Max for seven days
Follow Genetic Analysis with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Genetic Analysis
Your first answer is free, no account needed.
Do you own Genetic Analysis, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Genetic Analysis and a few more. Free, no card.
Super Stock+45.1%In short
- Genetic Analysis has fallen 37.0% over the past year, including dividends.
- Overall, Genetic Analysis ranks better than 8% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.1%. The price is 95.9% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 8% of Nordic stocks.
No. 167 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 147 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.38
- Asset turnoverSales divided by everything the company owns0.27
- Return on equityProfit divided by equity−62.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 108 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.7
- P/SPrice divided by sales3.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 131 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−26.1%
- 6 months−18.8%
- 9 months−24.4%
- 12 months−37.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Genetic Analysis
Genetic Analysis AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in NOK. It has around 18 employees.
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Feca…


See the full analysis of Genetic Analysis.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card